Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development

BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and sulindac are effective for colorectal cancer prevention in humans and some animal models, but concerns over gastro-intestinal (GI) ulceration and bleeding limit their potential for chemopreventive use in broader populatio...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Cancer
Päätekijät: Davis, Jennifer S., Kanikarla-Marie, Preeti, Gagea, Mihai, Yu, Patrick L., Fang, Dexing, Sebastian, Manu, Yang, Peiying, Hawk, Ernest, Dashwood, Roderick, Lichtenberger, Lenard M., Menter, David, Kopetz, Scott
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2020
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7488444/
https://ncbi.nlm.nih.gov/pubmed/32912193
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07311-4
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia